These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6705136)

  • 1. Repeated daunomycin administration in rats. Pharmacokinetics and bone marrow toxicity.
    Nooter K; Sonneveld P; Deurloo J; Oostrum R; Schultz F; Martens A; Hagenbeek A
    Cancer Chemother Pharmacol; 1984; 12(3):187-9. PubMed ID: 6705136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue distribution and myelotoxicity of daunomycin in the rat: rapid bolus injection vs continuous infusion.
    Nooter K; Sonneveld P; Martens A; Hagenbeek A; Schultz F
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):801-6. PubMed ID: 3770038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the pharmacokinetics of daunomycin in normal and leukemic rats.
    Nooter K; Sonneveld P; Martens A
    Cancer Res; 1985 Sep; 45(9):4020-5. PubMed ID: 4027999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of verapamil on the pharmacokinetics of daunomycin in the rat.
    Nooter K; Oostrum R; Deurloo J
    Cancer Chemother Pharmacol; 1987; 20(2):176-8. PubMed ID: 3664935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat.
    Huwyler J; Yang J; Pardridge WM
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1541-6. PubMed ID: 9316870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers.
    Kerr DJ; Hynds SA; Shepherd J; Packard CJ; Kaye SB
    Biochem Pharmacol; 1988 Oct; 37(20):3981-6. PubMed ID: 3190742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lipid metabolism in daunomycin-induced nephrotic rats (Part 6)].
    Gomikawa S; Inagaki O; Mori H; Inoue S; Takamitsu Y; Fujita Y
    Nihon Jinzo Gakkai Shi; 1993 Mar; 35(3):239-46. PubMed ID: 8501853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.
    Cusack BJ; Young SP; Olson RD
    Cancer Chemother Pharmacol; 1995; 35(3):213-8. PubMed ID: 7805179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative flow cytometric determination of anthracycline content of rat bone marrow cells.
    Nooter K; van den Engh G; Sonneveld P
    Cancer Res; 1983 Nov; 43(11):5126-30. PubMed ID: 6616450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daunomycin and daunomycinol plasma levels measured by HPLC after perfusions of daunomycin and daunomycin-DNA complex in rabbits: a preliminary report.
    Hulhoven R; Desager JP; Sokal G; Harvengt C
    Arch Int Pharmacodyn Ther; 1977 Apr; 226(2):344-5. PubMed ID: 879917
    [No Abstract]   [Full Text] [Related]  

  • 11. Kinetics of daunomycin in leukemia cells and leukocytes in vivo in the rat.
    Sonneveld P; Kokenberg E; van der Steuijt K; Nooter K
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1109-16. PubMed ID: 3477464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characteristics of daunomycin in antibiotic with antitumour action.
    Picone MA; Traina A
    Arzneimittelforschung; 1970 Jan; 20(1):88-92. PubMed ID: 5467450
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of razoxane (ICRF 159) on daunomycin (NSC 82151) metabolism and DNA complexation.
    Wang GM; Finch M
    Drug Chem Toxicol; 1980; 3(2):213-25. PubMed ID: 7227218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipid metabolism in daunomycin-induced nephrotic rats (5)].
    Gomikawa S; Inagaki O; Mori H; Fujita Y
    Nihon Jinzo Gakkai Shi; 1990 Sep; 32(9):985-93. PubMed ID: 2263029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daunomycin-arachidonic acid complex as a potential new antitumor agent.
    Sasaki T; Tsukada Y; Deutsch HF; Hirai H
    Cancer Chemother Pharmacol; 1984; 13(2):75-7. PubMed ID: 6205782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects.
    Schnyder A; Krähenbühl S; Drewe J; Huwyler J
    J Drug Target; 2005 Jun; 13(5):325-35. PubMed ID: 16199376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of daunomycin and adriamycin in mice. A comparative study.
    Rosso R; Esposito M; Sala R; Santi L
    Biomedicine; 1973 Jul; 19(7):304-7. PubMed ID: 4593553
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography.
    Hulhoven R; Desager JP
    J Chromatogr; 1976 Sep; 125(1):369-74. PubMed ID: 977683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.
    Speth PA; Linssen PC; Boezeman JB; Wessels HM; Haanen C
    Cancer Chemother Pharmacol; 1987; 20(4):311-5. PubMed ID: 3690804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a prolactin-daunomycin ligand as a probe for drug targeting.
    Blossey HC; Gayer B; Amir-Zaltsman Y; Kohen F
    Mol Cell Endocrinol; 1986 Aug; 46(3):245-52. PubMed ID: 3017783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.